SCIENCE-BOOK 29.04.2025 - Flipbook - Page 5
FILLERS
Safety profile
Summary of the publication:
Clinical experience with PEGylated Hyaluronic Acid
Fillers: A 3-year Retrospective Study
Authors: Rauso R. et al. I Published on 14.08.2021
The aim of the study was to determine the safety and efficacy of PEG cross-linked
HA-based filler retrospectively.
A total of 61 treatments using 124 vials of HA filler crosslinked with PEG were performed.
A retrospective clinical evaluation of the outcomes following PEG cross-linked
HA-based filler injection was performed.
RESULTS
No one claimed swelling in the post injective period.
No major complications, nor minor such as nodules were recorded.
No nodules or granuloma were recorded during the follow-up period.
Long-lasting result, even when the follow-up was up to 2 years.
No over-and underfilling was performed.
KEY MESSAGES
Pegylated ha filler provide long-lasting effect and a better resistance
to thermal and mechanical stress, high biocompability and safety.
The non-toxicity and non-immunogenicity of peg provides a lack
of allergic and immunological reaction.
Figure 1: A 45-year-old female mid and lower face contouring fillers. To the left of each pictures the pre-injection appearance, at the
center, a 1 month follow-up; to the right the 2 years follow-up; three-quarter right view.
No side effects related to immunogenicity were detected and total absence
of edema.
CONCLUSION
Figure 2: A 45-year-old female mid and lower face contouring fillers. To the left of each pictures the pre-injection appearance, at the
center a 1 month follow-up; to the right, the 2 years follow-up; three quarter left view.
Figure 3: A 45-year-old female mid and lower face contouring fillers. To the left of each pictures the pre-injection appearance, at the
center a 1 month follow-up; to the right the 2 years follow-up; lateral left view
Back to the safety profile page
Clinical outcomes of this article shows that in a 3-year period no granulomas,
foreign body reactions, nor other complications have been reported.
These results confirm the clinical outcomes of previous studies published
by Zerbinati et al.; PEGylated HA fillers have a high safety profile, a high
biocampatibility, and result in long-lasting clinical outcomes.
Reference: Rauso R, Nicoletti GF, Bove P, Rauso GM, Fragola R, Lo Giudice G, Zerbinati N. Clinical Experience with PEGylated Hyaluronic
Acid Fillers: A 3-year Retrospective Study. Open Access Maced J Med Sci. 2021 Oct 14; 9(B):1168-1173. https://doi.org/10.3889/
oamjms.2021.6457.
